Press Releases

InVivo Therapeutics to Present at Canaccord Genuity’s Medical Technologies & Diagnostics Forum

Published: November 6, 2017

CAMBRIDGE, Mass. (November 6, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 9, 2017 at 3:00 PM Eastern Time at the Westin New York Grand Central Hotel in Manhattan. Mr. Perrin will present an overview of the company’s Neuro-Spinal Scaffold™ program and discuss other recent business updates for the company during the presentation. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord […]

View Article
InVivo Therapeutics Provides Business Update and Reports 2017 Third Quarter Financial Results

Published: October 30, 2017

CAMBRIDGE, Mass. (October 30, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a general business update and reported financial results for the quarter ended September 30, 2017. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the third quarter, we focused our resources solely on reopening enrollment into the clinical study of the Neuro-Spinal Scaffold™ in complete thoracic spinal cord injury (SCI). As part of this focus, we reduced our workforce by 39%, which is expected to result in 2018 operating expense savings of approximately $7.3 million.” Mr. Perrin continued, “Enrollment into the INSPIRE study is currently on […]

View Article
InVivo Therapeutics Announces Oral Platform Presentation at 2017 Congress of Neurological Surgeons Annual Meeting

Published: October 10, 2017

CAMBRIDGE, Mass. (Oct 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Stuart Lee, M.D., Investigator at Vidant Medical Center in Greenville, North Carolina, will be giving an oral platform presentation titled “Histopathology of Necrotic Spinal Cord Tissue Exudate Collected During Surgical Implantation of a Biodegradable Scaffold Following Acute Spinal Cord Injury: Pre-clinical and Clinical Findings” at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting to be held October 7-11, 2017 in Boston, MA. The presentation will be made on Wednesday, October 11, during the Rapid-Exchange Oral Presentations, Session 2. Dr. Lee said, “The INSPIRE trial has allowed […]

View Article
InVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference

Published: September 20, 2017

CAMBRIDGE, Mass. (September 20, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 12:00pm ET at the Sofitel New York Hotel, in Manhattan. Mr. Perrin’s presentation will provide an overview of the company and discuss recent updates to the company’s Neuro-Spinal Scaffold™ program. A live webcast of the presentation will be available at http://wsw.com/webcast/ladenburg3/nviv/ and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 […]

View Article
InVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade

Published: September 5, 2017

– Costs substantially lower for patients with less severe AIS Grade – CAMBRIDGE, Mass. (September 5, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of an article titled “Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury” in the journal Neurosurgery. Neurosurgery is the official journal of the Congress of Neurological Surgeons. The article estimates the lifetime economic costs associated with hospitalizations in relation to American Spinal Injury Association Impairment Scale (AIS) grade. AIS grades are widely-used measures of spinal cord injury (SCI) severity that range from […]

View Article
InVivo Therapeutics Announces Strategic Corporate Restructuring

Published: August 28, 2017

–  Company Focuses Resources on INSPIRE  – CAMBRIDGE, Mass. (August 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it is executing a strategic restructuring in order to focus on The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury The strategic restructuring will allow the company to concentrate its efforts on reopening patient enrollment for INSPIRE, completing INSPIRE, and filing a Humanitarian Device Exemption (HDE) submission for the Neuro-Spinal Scaffold. The INSPIRE Study is designed to demonstrate the safety and […]

View Article
InVivo Therapeutics Announces Exchange of Certain Warrants for Common Stock

Published: August 10, 2017

– Eliminates Vast Majority of Adverse Warrants – CAMBRIDGE, Mass. (August 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that it had exchanged certain outstanding warrants that were issued as part of a financing in 2014 (the “2014 Warrants”) for shares of the company’s common stock. The 2014 Warrants have anti-dilution features such that the exercise price of the warrants decreases if the company sells shares of its common stock for consideration below the exercise price of the 2014 Warrants, and upon certain other events. In addition, the number of warrants increases inversely to the exercise price decrease. […]

View Article
InVivo Therapeutics Provides Business Update and Reports 2017 Second Quarter Financial Results

Published: August 8, 2017

CAMBRIDGE, Mass. (August 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a general business update and reported financial results for the quarter ended June 30, 2017. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the second quarter, we continued to make significant progress at InVivo. During the quarter, we enrolled four more patients into INSPIRE, and we now have 16 patients in follow-up. One of these patients improved from complete AIS A SCI to motor incomplete AIS C SCI at the one-month visit. We also announced that two patients who had previously converted to AIS B had […]

View Article
InVivo Therapeutics to Present at Canaccord Genuity’s 37th Annual Growth Conference

Published: August 8, 2017

CAMBRIDGE, Mass. (August 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the 37th Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017 at 2:30 PM Eastern Time at the InterContinental Boston in Boston, MA. This is the first time that the company has been invited to present at this conference. Mr. Perrin’s presentation will feature recent updates to the company’s Neuro-Spinal Scaffold™ program. A live webcast will be available at http://wsw.com/webcast/canaccord26/nviv and a webcast replay will be available at the same address approximately one hour after the […]

View Article
InVivo Therapeutics Announces Updates on the INSPIRE Study

Published: July 31, 2017

– Announces Two New Patient Conversions – – Implements Temporary Enrollment Halt – CAMBRIDGE, Mass. (July 31, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today provided an update on the progress of the company’s INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), which is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete thoracic spinal cord injury (SCI).  The primary endpoint of the study is defined as improvement in ASIA Impairment Scale (AIS) grade from […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.